Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InTTercePT: Tucatinib in HER2+ Breast Cancer
NCT05041842Phase 2Active, not recruiting
- Sponsor
- Unicancer
- Start
- Dec 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tucatinib in HER2-positive metastatic breast cancer, sponsored by Unicancer. Started Dec 2021; status: active, not recruiting.
02
Drugs
tucatinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT05041842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05041842.